NasdaqGS:RGNXBiotechs
Regenxbio (RGNX) Q4 US$67 Million Loss Tests Bullish Revenue Growth Narrative
REGENXBIO (RGNX) closed out FY 2025 with Q4 revenue of US$30.3 million and a basic EPS loss of US$1.30, alongside a trailing twelve month EPS loss of US$3.76 on revenue of US$170.4 million. Over recent periods, the company has seen quarterly revenue range from US$21.4 million to US$89.0 million, while basic EPS has swung between a small profit of US$0.12 and losses of more than US$1.30 per share. This sets up a story that is heavily driven by how much investors are prepared to tolerate...